Monitor for any unexpected CFO transition risks during the handover period, though the orderly transition and retention of Mackaness as consultant mitigate immediate concerns. Watch for changes in financial guidance or capital allocation strategy under new leadership.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $38.09entry
- T+1 · 9mo ago +2.57%α +3.03% · $39.07
- T+5 · 9mo ago +1.26%α +2.39% · $38.57
- T+20 · 8mo ago −16.36%α −9.95% · $31.86
- T+60 · 6mo ago +39.17%α +31.42% · $53.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Soleno Therapeutics announced the retirement of CFO James Mackaness and the appointment of Jennifer Fulk as incoming CFO, effective March 2, 2026. Fulk will receive a $525,000 base salary and equity awards totaling 106,860 shares. Mackaness will transition to a consulting role through year-end.
Key Facts
- Jennifer Fulk appointed CFO effective March 2, 2026
- James Mackaness retiring, will serve as consultant through December 31, 2026
- Fulk's compensation: $525,000 base salary, 67,660 stock options, 39,200 RSUs
- Fulk previously CFO at Talkspace and held executive roles at Eli Lilly
- No disagreement cited in Mackaness's departure
Financial Impact
Approximately $525,000 annual cash compensation plus equity awards valued at approximately $1.4 million at current stock price (based on 106,860 shares)
Risk Factors
- Potential disruption during CFO transition
- Increased compensation expenses
- Equity dilution from new grants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073209 |
| Document: d110816dex101.htm | 0001193125-26-073209 |
| Document: d110816dex991.htm | 0001193125-26-073209 |
| Document: 0001193125-26-073209-index-headers.html | 0001193125-26-073209 |
| Document: 0001193125-26-073209-index.html | 0001193125-26-073209 |
| Document: 0001193125-26-073209.txt | 0001193125-26-073209 |
Track record
10 reports on SLNO
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +2.57% at T+1 after the Feb 26, 2026 report. 2 of 4 went positive at some point.
Filters
- Jun 11, 202622w ago Institutional Cluster Bullish 6/10 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 No price data
- May 28, 202624w ago 15-12G Bearish 8/10 No price data
- May 28, 202624w ago EFFECT Bearish 5/10 No price data
- May 18, 202626w ago 8-K / 25-NSE Bullish 8/10 Entry $53.01 No price data
- Apr 7, 202631w ago 8-K Bearish 7/10 Entry $52.35 to $52.62 ▼ −0.52% +4.81% vs SPY
- Apr 6, 202632w ago 8-K Bullish 8/10 Entry $52.25 to $52.64 ▲ +0.75% −3.39% vs SPY
- Mar 27, 202633w ago Insider Cluster Neutral 3/10 Entry $30.05 to $52.25 ▲ +73.88% +70.01% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Entry $38.09 to $38.57 ▲ +1.26% +2.42% vs SPY
- Feb 26, 202637w ago 8-K Neutral 3/10 Viewing Entry $38.09 to $38.57 ▲ +1.26% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers